These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8637685)

  • 1. Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease.
    Tamesis RR; Rodriguez A; Christen WG; Akova YA; Messmer E; Foster CS
    Ophthalmology; 1996 May; 103(5):768-75. PubMed ID: 8637685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease.
    Lane L; Tamesis R; Rodriguez A; Christen W; Akova YA; Messmer E; Pedroza-Seres M; Barney N; Foster CS
    Ophthalmology; 1995 Oct; 102(10):1530-5. PubMed ID: 9097802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid.
    Miserocchi E; Baltatzis S; Roque MR; Ahmed AR; Foster CS
    Ophthalmology; 2002 Jan; 109(1):111-8. PubMed ID: 11772589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive drugs in immune and inflammatory ocular disease.
    Hemady R; Tauber J; Foster CS
    Surv Ophthalmol; 1991; 35(5):369-85. PubMed ID: 2038720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Eye and corticosteroid's use].
    Fel A; Aslangul E; Le Jeunne C
    Presse Med; 2012 Apr; 41(4):414-21. PubMed ID: 22377461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide for ocular inflammatory diseases.
    Pujari SS; Kempen JH; Newcomb CW; Gangaputra S; Daniel E; Suhler EB; Thorne JE; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Foster CS
    Ophthalmology; 2010 Feb; 117(2):356-65. PubMed ID: 19969366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.
    Jabs DA; Rosenbaum JT; Foster CS; Holland GN; Jaffe GJ; Louie JS; Nussenblatt RB; Stiehm ER; Tessler H; Van Gelder RN; Whitcup SM; Yocum D
    Am J Ophthalmol; 2000 Oct; 130(4):492-513. PubMed ID: 11024423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy.
    Thorne JE; Woreta FA; Jabs DA; Anhalt GJ
    Ophthalmology; 2008 Dec; 115(12):2146-2152.e1. PubMed ID: 18930554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease.
    Baker KB; Spurrier NJ; Watkins AS; Smith JR; Rosenbaum JT
    Br J Ophthalmol; 2006 Dec; 90(12):1481-5. PubMed ID: 16914474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticosteroid-sparing strategies in the treatment of retinal vasculitis in systemic lupus erythematosus.
    Neumann R; Foster CS
    Retina; 1995; 15(3):201-12. PubMed ID: 7569347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety.
    Durrani K; Papaliodis GN; Foster CS
    Ophthalmology; 2004 May; 111(5):960-5. PubMed ID: 15121375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis--report of three cases.
    Kanzler S; Gerken G; Dienes HP; Meyer zum Büschenfelde KH; Lohse AW
    Z Gastroenterol; 1997 Jul; 35(7):571-8. PubMed ID: 9273991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and prognosis of myasthenia gravis in older people.
    Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
    J Am Geriatr Soc; 2000 Nov; 48(11):1442-8. PubMed ID: 11083321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive therapy in ocular cicatricial pemphigoid.
    Mondino BJ; Brown SI
    Am J Ophthalmol; 1983 Oct; 96(4):453-9. PubMed ID: 6353928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic drugs in systemic autoimmune diseases.
    Mathieu A; Carcassi U
    Clin Exp Rheumatol; 1989; 7 Suppl 3():S181-6. PubMed ID: 2691154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
    Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
    Daoud YJ; Amin KG
    Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of non infectious ocular inflammatory disease with low doses of cyclosporin A].
    Cuchacovich M; Gatica H; Verdaguer JI; Carreño MA; Villarroel F; Verdaguer J
    Rev Med Chil; 1999 Mar; 127(3):277-85. PubMed ID: 10436711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study.
    Desai RJ; Bateman BT; Huybrechts KF; Patorno E; Hernandez-Diaz S; Park Y; Dejene SZ; Cohen J; Mogun H; Kim SC
    BMJ; 2017 Mar; 356():j895. PubMed ID: 28264814
    [No Abstract]   [Full Text] [Related]  

  • 20. Mycophenolate mofetil therapy for inflammatory eye disease.
    Thorne JE; Jabs DA; Qazi FA; Nguyen QD; Kempen JH; Dunn JP
    Ophthalmology; 2005 Aug; 112(8):1472-7. PubMed ID: 16061096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.